C2N Diagnostics

C2N Diagnostics, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the Alzheimer’s and Parkinson’s Diseases Conference in Vienna, Austria on April 5.   Please join us in Vienna and be among the first to learn about exciting new data for the Precivity™ line of blood tests. 12:25 – 12:40 PRECIVITYAD2 TEST ACCURATELY IDENTIFIES BRAIN AMYLOID AND TAU PATHOLOGY IN ADNI PARTICIPANTS ENROLLED IN THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH STUDY. (ID 2534) Room: Hall F2 Presenter: Philip Verghese (United States of America) #ADPD2025 #ADPD #AlzheimersParkinsons #ADdiagnostics #ADPDVienna #brainhealth #brainamyloid #ADNI

It’s an important final day of the Alzheimer’s and Parkinson’s Diseases Conference in Vienna, Austria. Here’s where to learn about C2N Diagnostics data that presenters will highlight in sessions: 8:40 – 8:55 SMALL MOLECULE TARGETING OF THE P75 NEUROTROPHIN RECEPTOR MODULATES TAU MECHANISMS IN MOUSE AND HUMAN TRIALS (ID 64) Room: Hall B Presenter: Frank M. Longo (United States of America)   9:55 – 10:10 MEASUREMENT OF CSF MTBR-TAU243 IN CLINICAL TRIALS OF ALZHEIMER’S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY (ID 3096) Room: Hall F1 Presenter: Julie Czerkowicz (United States of America)   12:40 – 12:55 CLINICAL TRIAL DESIGN FOR CONCURRENT ANTI-AMYLOID AND ANTI-TAU ANTIBODY THERAPY FOR SPORADIC ALZHEIMER’S DISEASE (ID 2228) Room: Hall A Presenter: Thomas Doherty (United Kingdom) #ADPD2025 #ADPD #AlzheimersParkinsons #ADdiagnostics #ADPDVienna #brainhealth #bloodbiomakers #amyloid #precisionmedicine 

Two sessions today at the Alzheimer’s and Parkinson’s Diseases Conference in Vienna, Austria, will feature C2N Diagnostics data. 8:55 – 9:10  EVALUATION OF PLASMA PHOSPHO-TAU217 FOR ALZHEIMER’S DISEASE USING A FULLY AUTOMATED PLATFORM – INTERNATIONAL MULTI-CENTER STUDY IN PRIMARY AND SECONDARY CARE (ID 709) Room: Hall F2 Presenter: Sebastian Palmqvist (Sweden) 15:35 – 15:50 PRE-RECORDED: EARLY LIFE EXPERIENCES AND CURRENT STRESS INFLUENCE FLUID BIOMARKERS OF ALZHEIMER DISEASE (ID 73) Room: Hall E Presenter: John C. Morris (United States of America) C2N is a pioneer in advanced brain health diagnostics and continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at AD/PD.  #ADPD2025 #ADPD #AlzheimersParkinsons #ADdiagnostics #ADPDVienna #brainhealth #bloodbiomakers #amyloid #precisionmedicine 

A session at the Alzheimer’s and Parkinson’s Diseases Conference today in Vienna, Austria, will feature C2N Diagnostics data. C2N is a pioneer in advanced brain health diagnostics and continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at AD/PD. All sessions and posters will be held at the Austria Center Vienna. 15:35 – 15:50 PLASMA PTAU217 RATIO PREDICTS THE FUTURE PROGRESSION OF BRAIN TAU ACCUMULATION IN EARLY ALZHEIMER’S DISEASE (ID 1951) Room: Hall F1 Presenter: Viswanath Devanarayan (United States of America) #ADPD2025 #ADPD #AlzheimersParkinsons #ADdiagnostics #ADPDVienna #brainhealth

C2N CEO Joel Braunstein, MD will be speaking today at AD/PD.   Join him from 13:00 – 13:30 for “Transforming Alzheimer’s Disease Diagnosis with The PrecivityAD2™ Blood Test: Seeking to Establish a New Clinical Care Standard for Patients with Memory Impairment (ID 3284).”   Dr. Braunstein will be speaking at the Exhibition/Product Theater. #ADPD2025 #ADPD #AlzheimersParkinsons #ADdiagnostics #ADPDVienna #ADPDproducttheater #brainhealth

Joel Braunstein, MD, CEO of C2N, presented at the ADDF Diagnostics Accelerator (DxA) Day as part of the AD/PD Conference in Vienna, Austria. His panel discussed the Current Diagnostic Landscape for Alzheimer’s, from Development to Implementation. C2N will have daily posts on the 12 conference sessions that include C2N data. #ADPD2025 #ADPD #AlzheimersParkinsons #ADdiagnostics #ADPDVienna #brainhealth

C2N Diagnostics, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the Alzheimer’s and Parkinson’s Diseases Conference in Vienna, Austria April 1-5.   C2N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at AD/PD. Please join us in Vienna and be among the first to learn about exciting new data for the Precivity™ line of blood tests. All sessions and posters will be held at the Austria Center Vienna. C2N will be part of 12 sessions and offer 6 posters that will offer novel insights relating to the Precivity™ blood tests. Click here to learn more: https://lnkd.in/eiDp4cAe #ADPD2025 #ADPD #AlzheimersParkinsons #ADdiagnostics #ADPDVienna #ADPDposter #brainhealth

Splash Clinical and C2N Diagnostics Partner to Transform Global Clinical Trial Recruitment for Alzheimer's Disease The first-of-its-kind partnership combines Splash's recruitment platform with C2N's innovative blood tests to accelerate clinical research and improve patient experience. Under the partnership, Splash Clinical will provide a new clinical trial recruitment program that combines Splash's proprietary recruitment infrastructure with C2N's PrecivityAD2™ blood tests. The tests help healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease. "C2N Diagnostics prides itself on collaborating with the leading entities and researchers in the world to better understand the causes of Alzheimer’s disease as well as ways to better diagnose and treat it. This is why we’re excited to partner with Splash and its patient-centric platform focus,” said Joel Braunstein, MD, C2N CEO. “C2N assays have been used in over 150 Alzheimer’s disease and other research studies, and we’re confident even more clinical trials will benefit as a result of this new initiative that seeks to ease recruitment and accuracy for all involved.” https://lnkd.in/e7xZZVrD #clinicaltrials #SplashClinical #clinicaltrialrecruitment #bloodtests #Alzheimersresearch #amyloid #precisionmedicine  

C2N Diagnostics announces a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation (collectively hereinafter referred to as “Samsung”). C2N says Samsung’s decision bolsters its ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health. Jaywoo Kim, Executive Vice President of Samsung C&T Corporation, says, “Since Samsung C&T stepped into the life sciences industry by investing in biologics CDMO and biosimilar business, it has contributed to the stabilization of the biopharmaceutical supply chain and better access to high quality bio pharmaceutics. The investment into C2N Diagnostics shows Samsung’s continued dedication to future growth in the Life Science sector by seeking new business opportunities based on intelligent analytics and uniquely special diagnostics technologies. We are confident that C2N Diagnostics will further grow its leading position in the industry by serving global biopharma customers as well as medical service providers with its well-established blood biomarker testing portfolio.” https://lnkd.in/erb9KsmJ #Samsung #SamsungCTCorporation #investment #clinicallabservices #lifesciences #bloodbiomarker #brainhealth

Joel Braunstein, MD, CEO of C2N Diagnostics, will chair a meeting session and also speak Wednesday, March 11, at Precision Med TRI-CON; the conference “has served as the leading international meeting place for the diagnostics and precision medicine community.”   He’ll discuss “The Emergence of High-Performance Blood Biomarkers to Transform Clinical Diagnosis in Alzheimer’s Disease: Lessons from the PrecivityAD2 Blood Test.”   The conference session is titled “Precision Medicine Beyond Oncology: Diagnostics and Personalized Medicine in Immunology, Neurology, and Metabolic Diseases,” and it opens at 2 p.m. PT.   Dr. Braunstein will provide the opening session remarks and will present his topic at 2:35 p.m. PT on March 11. https://lnkd.in/gnkFYWex   #PrecisionMedTRICON #TriConference #TRICON #clinicaldiagnosis #precisionmedicine